AR035078A1 - Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas - Google Patents
Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonasInfo
- Publication number
- AR035078A1 AR035078A1 ARP020100288A ARP020100288A AR035078A1 AR 035078 A1 AR035078 A1 AR 035078A1 AR P020100288 A ARP020100288 A AR P020100288A AR P020100288 A ARP020100288 A AR P020100288A AR 035078 A1 AR035078 A1 AR 035078A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- group
- aryl
- heterocycle
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 101100173726 Arabidopsis thaliana OR23 gene Proteins 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229930013356 epothilone Natural products 0.000 abstract 4
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 101100495913 Arabidopsis thaliana CHR17 gene Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 102200033028 rs587777512 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos para incrementar la biodisponibilidad de las epotilonas administradas oralmente. Las epotilonas administradas por los métodos de la presente son suficientemente biodisponibles como para tener efecto farmacológico. La presente también se refiere a composiciones farmacéuticas, formas farmacéuticas de dosificación y equipos para usar en los métodos de la misma. Dichas epotilonas tienen las fórmulas (1) ó (2) en las cuales: G se selecciona del grupo integrado por alquilo, alquil sustituido, arilo, arilo sustituido, heterociclo, o un resto de las fórmulas (a), (b) y (c); W es O ó NR16; X es O; S; CHR17; ó H, R18; Y se selecciona del grupo integrado por O; H, H; H, OR22; OR23, OR23; NOR24; H, NOR25; H, HNR26R27; NHNR28R29; H, NHNR30R31 ó CHR32, en donde OR23, OR23 puede ser un cetal cíclico;B1 y B2 se seleccionan del grupo integrado por H, OR33, OCOR34, OCONR35R36, NR37R38 ó NR39CONR40R41; D se selecciona del grupo integrado por NR42R43 o heterociclo; R1, R2, R3, R4 y R5 se seleccionan de H ó alquilo inferior; R8, R9, R10 y R11 se seleccionan del grupo integrado por H, alquilo, alquilo sustituido, arilo, arilo sustituido, cicloalquilo, heterociclo o heterociclo sustituido; R17, R18, R22 y R23 se seleccionan del grupo integrado por H, alquilo y alquilo sustituido; R24, R25, R26, R28, R30, R32, R33, R34, R35, R36, R37, R39, R40, R41, R42, R51, R52, R53 y R61 se seleccionan del grupo de H, alquilo, alquilo sustituido, arilo o arilo sustituido; R12, R16, R27, R29, R31, R38 y R43 se seleccionan del grupo integrado por H, alquilo, alquilo sustituido, arilo, arilo sustituido, cicloalquilo, heterociclo, R51C=O, R52OC=O, R53SO2, hidroxi y O-alquilo u O-alquilo sustituido; o una sal, solvato, clatrato, hidrato o prodroga farmacéuticamente aceptable de las mismas. Dichas epotilonas se administran oralmente con uno o más buffers, neutralizantes de ácidos, farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26422801P | 2001-01-25 | 2001-01-25 | |
| US29001901P | 2001-05-11 | 2001-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035078A1 true AR035078A1 (es) | 2004-04-14 |
Family
ID=26950349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100288A AR035078A1 (es) | 2001-01-25 | 2002-01-25 | Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6576651B2 (es) |
| EP (1) | EP1361877A1 (es) |
| JP (1) | JP2004528287A (es) |
| KR (1) | KR20040025888A (es) |
| CN (1) | CN1268336C (es) |
| AR (1) | AR035078A1 (es) |
| BG (1) | BG108027A (es) |
| BR (1) | BR0206695A (es) |
| CA (1) | CA2434584A1 (es) |
| CZ (1) | CZ20032023A3 (es) |
| EE (1) | EE200300329A (es) |
| HR (1) | HRP20030674A2 (es) |
| HU (1) | HUP0303800A3 (es) |
| IL (1) | IL156759A0 (es) |
| IS (1) | IS6892A (es) |
| MX (1) | MXPA03006476A (es) |
| NO (1) | NO20033343L (es) |
| NZ (1) | NZ526871A (es) |
| PE (1) | PE20020853A1 (es) |
| PL (1) | PL368636A1 (es) |
| RU (1) | RU2291695C2 (es) |
| SK (1) | SK9212003A3 (es) |
| TW (1) | TWI250017B (es) |
| UY (1) | UY27138A1 (es) |
| WO (2) | WO2002058699A1 (es) |
| YU (1) | YU58103A (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| CA2374944A1 (en) | 1999-06-10 | 2000-12-21 | Nigel Hacker | Spin-on-glass anti-reflective coatings for photolithography |
| US6824879B2 (en) | 1999-06-10 | 2004-11-30 | Honeywell International Inc. | Spin-on-glass anti-reflective coatings for photolithography |
| US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| CA2434566A1 (en) * | 2001-01-25 | 2002-08-15 | Timothy M. Malloy | Parenteral formulation containing epothilone analogs |
| PL363362A1 (en) | 2001-02-20 | 2004-11-15 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
| EP1383490B1 (en) * | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
| JP4381143B2 (ja) | 2001-11-15 | 2009-12-09 | ハネウェル・インターナショナル・インコーポレーテッド | フォトリソグラフィー用スピンオン反射防止膜 |
| WO2003077903A1 (en) * | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| ATE450534T1 (de) | 2002-08-23 | 2009-12-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO2004032866A2 (en) * | 2002-10-09 | 2004-04-22 | Kosan Biosciences, Inc. | Therapeutic formulations |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| HUE029382T2 (en) * | 2003-08-26 | 2017-02-28 | Shire Biopharmaceuticals Holdings Ireland Ltd | Pharmaceutical composition containing lanthanum compounds |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| AU2004291107B2 (en) * | 2003-11-14 | 2010-09-30 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| US8053159B2 (en) | 2003-11-18 | 2011-11-08 | Honeywell International Inc. | Antireflective coatings for via fill and photolithography applications and methods of preparation thereof |
| US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
| US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
| US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
| KR20070084325A (ko) * | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
| EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8642246B2 (en) | 2007-02-26 | 2014-02-04 | Honeywell International Inc. | Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof |
| CL2009000990A1 (es) | 2008-04-24 | 2010-10-15 | Bristol Myers Squibb Co | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. |
| US8557877B2 (en) | 2009-06-10 | 2013-10-15 | Honeywell International Inc. | Anti-reflective coatings for optically transparent substrates |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| US8864898B2 (en) | 2011-05-31 | 2014-10-21 | Honeywell International Inc. | Coating formulations for optical elements |
| CN102276433B (zh) * | 2011-06-30 | 2016-04-20 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
| JP6803842B2 (ja) | 2015-04-13 | 2020-12-23 | ハネウェル・インターナショナル・インコーポレーテッドＨｏｎｅｙｗｅｌｌ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃ． | オプトエレクトロニクス用途のためのポリシロキサン製剤及びコーティング |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
| DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
| DK0873341T3 (da) | 1995-11-17 | 2004-01-19 | Biotechnolog Forschung Gmbh | Epothilonderivater, fremstilling og anvendelse |
| PL189698B1 (pl) * | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
| DE19636343C1 (de) * | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
| DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
| JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
| WO1998022461A1 (de) | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
| DE59805110D1 (de) | 1997-02-25 | 2002-09-12 | Biotechnolog Forschung Gmbh | Seitenkettenmodifizierte epothilone |
| DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
| JP4065573B2 (ja) | 1997-04-18 | 2008-03-26 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
| DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| EP1001951B1 (de) | 1997-07-16 | 2002-09-25 | Schering Aktiengesellschaft | Thiazolderivate, verfahren zur herstellung und verwendung |
| CA2299608A1 (en) | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| BR9907647B1 (pt) | 1998-02-05 | 2014-04-01 | Novartis Ag Novartis S A Novartis Inc | Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| CN100381566C (zh) | 1998-11-20 | 2008-04-16 | 科森生物科学公司 | 产生环氧噻酮及其衍生物的重组方法和材料 |
| ES2207983T3 (es) | 1998-12-22 | 2004-06-01 | Novartis Ag | Derivados de epotilona y su uso como agentes antitumorales. |
| DE50014587D1 (de) | 1999-02-18 | 2007-10-04 | Bayer Schering Pharma Ag | 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
| IL156578A0 (en) | 2001-01-25 | 2004-01-04 | Bristol Myers Squibb Co | A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| EP1383490B1 (en) | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
-
2002
- 2002-01-22 NZ NZ526871A patent/NZ526871A/en unknown
- 2002-01-22 WO PCT/US2002/001693 patent/WO2002058699A1/en not_active Ceased
- 2002-01-25 PL PL02368636A patent/PL368636A1/xx not_active Application Discontinuation
- 2002-01-25 WO PCT/US2002/002518 patent/WO2002058701A1/en not_active Ceased
- 2002-01-25 YU YU58103A patent/YU58103A/sh unknown
- 2002-01-25 KR KR10-2003-7009781A patent/KR20040025888A/ko not_active Withdrawn
- 2002-01-25 HR HR20030674A patent/HRP20030674A2/hr not_active Application Discontinuation
- 2002-01-25 CZ CZ20032023A patent/CZ20032023A3/cs unknown
- 2002-01-25 CN CNB028069927A patent/CN1268336C/zh not_active Expired - Fee Related
- 2002-01-25 MX MXPA03006476A patent/MXPA03006476A/es unknown
- 2002-01-25 EE EEP200300329A patent/EE200300329A/xx unknown
- 2002-01-25 IL IL15675902A patent/IL156759A0/xx unknown
- 2002-01-25 AR ARP020100288A patent/AR035078A1/es unknown
- 2002-01-25 HU HU0303800A patent/HUP0303800A3/hu unknown
- 2002-01-25 EP EP02723073A patent/EP1361877A1/en not_active Withdrawn
- 2002-01-25 BR BR0206695-5A patent/BR0206695A/pt not_active IP Right Cessation
- 2002-01-25 UY UY27138A patent/UY27138A1/es not_active Application Discontinuation
- 2002-01-25 PE PE2002000061A patent/PE20020853A1/es not_active Application Discontinuation
- 2002-01-25 SK SK921-2003A patent/SK9212003A3/sk unknown
- 2002-01-25 CA CA002434584A patent/CA2434584A1/en not_active Abandoned
- 2002-01-25 JP JP2002559035A patent/JP2004528287A/ja not_active Withdrawn
- 2002-01-25 RU RU2003126174/15A patent/RU2291695C2/ru not_active IP Right Cessation
- 2002-01-25 US US10/057,390 patent/US6576651B2/en not_active Ceased
- 2002-01-25 TW TW091101287A patent/TWI250017B/zh not_active IP Right Cessation
-
2003
- 2003-07-24 NO NO20033343A patent/NO20033343L/no not_active Application Discontinuation
- 2003-07-24 BG BG108027A patent/BG108027A/bg unknown
- 2003-07-24 IS IS6892A patent/IS6892A/is unknown
-
2005
- 2005-06-09 US US11/149,501 patent/USRE40387E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1268336C (zh) | 2006-08-09 |
| WO2002058701A1 (en) | 2002-08-01 |
| RU2291695C2 (ru) | 2007-01-20 |
| BG108027A (bg) | 2004-12-30 |
| CN1498106A (zh) | 2004-05-19 |
| HRP20030674A2 (en) | 2005-06-30 |
| BR0206695A (pt) | 2004-04-20 |
| KR20040025888A (ko) | 2004-03-26 |
| US6576651B2 (en) | 2003-06-10 |
| CZ20032023A3 (cs) | 2005-03-16 |
| HUP0303800A3 (en) | 2005-02-28 |
| NZ526871A (en) | 2006-01-27 |
| MXPA03006476A (es) | 2003-09-22 |
| RU2003126174A (ru) | 2005-02-27 |
| JP2004528287A (ja) | 2004-09-16 |
| TWI250017B (en) | 2006-03-01 |
| CA2434584A1 (en) | 2002-08-01 |
| YU58103A (sh) | 2006-03-03 |
| EE200300329A (et) | 2003-10-15 |
| US20020177615A1 (en) | 2002-11-28 |
| SK9212003A3 (en) | 2004-11-03 |
| EP1361877A1 (en) | 2003-11-19 |
| IL156759A0 (en) | 2004-02-08 |
| AU2002253880B2 (en) | 2006-11-09 |
| PL368636A1 (en) | 2005-04-04 |
| NO20033343L (no) | 2003-09-24 |
| NO20033343D0 (no) | 2003-07-24 |
| HUP0303800A2 (hu) | 2004-03-29 |
| WO2002058699A1 (en) | 2002-08-01 |
| PE20020853A1 (es) | 2002-09-27 |
| UY27138A1 (es) | 2002-08-30 |
| IS6892A (is) | 2003-07-24 |
| USRE40387E1 (en) | 2008-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035078A1 (es) | Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas | |
| ES2496099T3 (es) | El uso de amisulprida para el tratamiento de náuseas y vómitos inducidos por la quimioterapia | |
| ES2576497T3 (es) | Compuesto de piperidina novedoso o sal del mismo | |
| ES2608285T3 (es) | Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC | |
| ES2416304T3 (es) | Derivado de 2-acilaminotiazol o sal del mismo | |
| ES2219342T3 (es) | Nuevo uso de 1-(5-cianoindol-3-il)butil)-4-(2-carbamoilbenzofuran-5-il)-piperazina y sus sales fisiologicamente aceptables para el tratamiento de trastornos bipolares y mania. | |
| ES2829907T3 (es) | Inhibidores novedosos de la replicación viral | |
| ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| CU23967B1 (es) | Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial | |
| CA2483998A1 (en) | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | |
| AU2006226554B2 (en) | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| RU2008150613A (ru) | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы | |
| ES2673158T3 (es) | Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| UY32562A (es) | Pirimidinas sustituidas por imidazol 724 | |
| WO2021168483A3 (en) | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | |
| JP2012525437A5 (es) | ||
| UY39171A (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal farmacéuticamente aceptable, hidrato, o solvato de esta | |
| ES2579628T3 (es) | Iminoazúcares y métodos de tratamiento de enfermedades virales | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| WO2020117755A1 (en) | Compositions and methods for treating biofilms | |
| ES2351665T3 (es) | Derivados de benzamidina para el tratamiento y la prevención de mucositis. | |
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам | |
| JP2013525290A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |